Drawing for OPSONIX

USPTO serial 87310296

OPSONIX

Reviewed by CopyMark Law Group

Reg. 5466486Status 710
Filing date
Status date
Registration date
May 8, 2018
Examiner
CHANG, ELIZABETH YI HSUAN
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with OPSONIX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Ann Lamport Hammitte

Ann Lamport Hammitte Lando & Anastasi, LLP60 State Street, 23rd FloorBoston, MA 02109UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Diagnostic preparations for scientific or research use; diagnostic preparations for clinical or medical laboratory use; assays for research purposesSECTION 8 - CANCELLEDNov 14, 2017
005Biological products containing recombinant proteins for the diagnosis of infections; biological products containing recombinant proteins for the diagnosis of bloodstream infections; biological products containing recombinant proteins for the diagnosis of sepsis; diagnostic agents, preparations and substances for bloodstream infections; biological products containing recombinant proteins for diagnosis of bloodstream infections; biological products containing recombinant proteins for medical diagnosis purposes; diagnostic preparations for medical purposes; medical diagnostic assays for testing of blood; diagnostic preparations for medical purposes for detecting the presence of infectious agents and toxins in bloodSECTION 8 - CANCELLEDNov 14, 2017

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 22, 2024C8..CANCELLED SEC. 8 (6-YR)—
May 8, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Nov 16, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 16, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 16, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 8, 2018R.SRREGISTERED-SUPPLEMENTAL REGISTERYour mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application.
Apr 2, 2018PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 26, 2018ALIEASSIGNED TO LIE—
Mar 20, 2018AAUANOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE MAILED—
Mar 19, 2018EXPTEXPARTE APPEAL TERMINATED—
Mar 19, 2018CNTAAPPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER—
Mar 19, 2018IUAAUSE AMENDMENT ACCEPTED—
Mar 16, 2018AUPCAMENDMENT TO USE PROCESSING COMPLETE—
Mar 16, 2018IUAFUSE AMENDMENT FILED—
Mar 15, 2018EAAUTEAS AMENDMENT OF USE RECEIVED—
Mar 15, 2018ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Mar 15, 2018EXPIEX PARTE APPEAL-INSTITUTED—
Mar 15, 2018JURTJURISDICTION RESTORED TO EXAMINING ATTORNEY—
Mar 15, 2018EXAFEXPARTE APPEAL RECEIVED AT TTAB—
Sep 18, 2017CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 16, 2017CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 6, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 5, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 5, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 30, 2017CEAPEXAMINER'S AMENDMENT/PRIORITY ACTION MAILED—
May 30, 2017CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
May 29, 2017EPENCOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY—
May 1, 2017CPRAPRIORITY ACTION MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Apr 28, 2017CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Apr 18, 2017DOCKASSIGNED TO EXAMINER—
Jan 27, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 26, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance